ABT:NYSEAbbott Laboratories Analysis

Abbott Laboratories is trading at $84.47, well below its 20‑day ($88.74), 50‑day ($98.28) and 200‑day ($118.54) moving averages, indicating a pronounced bearish technical backdrop. However, the RSI of 30.4 signals oversold conditions and the MACD histogram has turned positive, suggesting a potential short‑term rebound toward the $81.97 support level. Fundamentally, revenue grew 7.8% YoY to $45.1B with solid gross (56.5%) and operating margins (13.5%), and free cash flow remains healthy at $6.34B, supporting the 2.98% dividend (payout ~67%). The forward PE of 13.9x is well below the sector average of 26.7x, and analysts maintain a “Buy” consensus with a median price target of $120, implying ~40% upside from current levels.
The DCF‑derived fair value of $51.55 suggests the market may be overpaying relative to intrinsic estimates, while the company carries a high debt‑to‑equity ratio (~65%) that warrants monitoring. Recent news shows a modest price‑target reduction by Barclays to $143 (still overweight) and a guidance cut, but the stock remains at a 10‑year valuation low, offering a compelling entry point for investors comfortable with the sector’s regulatory environment and the company’s diversified healthcare exposure.